TPST-1495

N/A

Report date: 2026/04/04 20:00:24
NME

Base Information

Drug NameTPST-1495
Drug Alias NameTPST-1495
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid EP2 receptor antagonistsProstanoid EP4 receptor antagonists
TargetsProstanoid EP4 receptorProstanoid EP2 receptor
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursEndometrial Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTempest Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of OklahomaNational Cancer InstituteTempest Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursEndometrial Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A